Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
Price : $35 *
At a glance
- Drugs Flumatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 24 Feb 2018 Status changed from recruiting to completed.
- 05 Aug 2014 New trial record